Contineum Therapeutics (CTNM)

• Market cap: $495M
• 1 day: -2.45%
• 5 days: -11.73%
• 1 month: -11.33%
• 3 months: 8.32%
• 6 months: 8.15%
• Year to date: 18.88%
• 1 year: 82.97%
• 5 years: -12.08%
• 10 years: -12.08%
• Sector: Healthcare
• Industry: Biotechnology

About: Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Employees: 41